Results 201 to 210 of about 15,971,534 (326)

Reconceptualizing Peri-Implantitis: Dual-Factor Inflammation and Its Role in Advancing Biomaterial Coatings. [PDF]

open access: yesClin Implant Dent Relat Res
Cunha DM   +6 more
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer   +14 more
wiley   +1 more source

Nerve tissue model on a micropatterned surface: Axon guidance and neural regeneration. [PDF]

open access: yesJ Mater Sci Mater Med
Arslantunali-Sahin D   +10 more
europepmc   +1 more source

Application-specific worst case corners using response surfaces and statistical models

open access: yesIEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, 2004
M. Sengupta   +5 more
semanticscholar   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo   +9 more
wiley   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Adaptive ionic liquid polymer microwave modulation surface with reprogrammable dielectric properties. [PDF]

open access: yesNat Commun
Dong Q   +8 more
europepmc   +1 more source

Developmental, Neuroanatomical and Cellular Expression of Genes Causing Dystonia

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Dystonia is one of the most common movement disorders, with variants in multiple genes identified as causative. However, an understanding of which developmental stages, brain regions, and cell types are most relevant is crucial for developing relevant disease models and therapeutics.
Darren Cameron   +5 more
wiley   +1 more source

Preload-Free Conformal Integration of Tactile Sensors on the Fingertip's Curved Surface. [PDF]

open access: yesBiomimetics (Basel)
Liu L   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy